Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.63M.
Undervalued
The company’s latest PE is -3.14, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 123.80M shares, increasing 5.44% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 6.59M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.31.